{
    "info": {
        "nct_id": "NCT03516812",
        "official_title": "Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer",
        "inclusion_criteria": "* Must be willing to provide informed consent prior to any study specific procedures\n* Documented histologically confirmed adenocarcinoma of the prostate\n* Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e., ≤ 50 mg/dL)\n* PSA must be at least 1 ng/ml and rising on two successive measurements at least two weeks apart\n* Patients must have progressed on abiraterone and/or enzalutamide; there must be at least a 3-week washout period after stopping the most recent approved therapy for mCRPC (i.e., abiraterone, enzalutamide, Ra-223, sipuleucel-t); if applicable, patients should be weaned off steroids at least 1 week prior to starting treatment\n* No prior chemotherapy for the treatment of mCRPC; patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer\n* Prior treatment with non-chemotherapy investigational agents is permitted; there must be at least a 3-week washout period after stopping any investigational cancer agent\n* Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days (within 28 days prior to administration of study treatment)\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (within 28 days prior to administration of study treatment)\n* Platelet count ≥ 100 x 10^9/L (within 28 days prior to administration of study treatment)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5 x ULN (within 28 days prior to administration of study treatment)\n* Patients must have creatinine clearance estimated using the Cockcroft-Gault equation or based on a 24 hour urine test of ≥ 51 mL/min (within 28 days prior to administration of study treatment)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Patients must have a life expectancy ≥ 16 weeks\n* Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations\n* At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment\n* Must have archival tissue available, be willing to undergo metastatic biopsy or have a sufficient plasma circulating tumor DNA (ctDNA) concentration in order to perform next-generation DNA sequencing\n* The study will require that 50% of enrolled subjects have homozygous deletions, deleterious mutations, or both in one or more of the DNA damage response (DDR) genes; the other 50% of patients must have an intact DDR pathway\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)\n* Previous enrollment in this study\n* Participation in another clinical study with an investigational product during the last 3 weeks\n* Any previous treatment with poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, including olaparib\n* Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years except: adequately treated non-melanoma skin cancer\n* Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome\n* Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment\n* Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil); the required washout period prior to starting olaparib is 2 weeks\n* Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents\n* Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia\n* Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)\n* Patients with symptomatic uncontrolled brain metastases; a scan to confirm the absence of brain metastases is not required; the patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment; patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days\n* Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, history of prior myocardial infarction, uncontrolled major seizure disorder, uncontrolled hypertension (blood pressure [BP] ≥ 160/100), history of prior stroke, uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7), unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication\n* Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)\n* Patients with a known hypersensitivity to olaparib or any of the excipients of the product\n* Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product\n* Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)\n* Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)\n* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study\n* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule\n* Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction)\n* Patients with pain attributable to their prostate cancer\n* Tumor causing urinary outlet obstruction that requires catheterization for voiding; patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll\n* Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation\n* Patients with NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) prior to enrollment in the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Must be willing to provide informed consent prior to any study specific procedures",
                "criterions": [
                    {
                        "exact_snippets": "Must be willing to provide informed consent prior to any study specific procedures",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must be willing to provide informed consent prior to any study specific procedures",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study specific procedures"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be willing to provide informed consent prior to any study specific procedures",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "willingness to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must be willing to provide informed consent prior to any study specific procedures",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study specific procedures"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with non-chemotherapy investigational agents is permitted; there must be at least a 3-week washout period after stopping any investigational cancer agent",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with non-chemotherapy investigational agents is permitted",
                        "criterion": "prior treatment with non-chemotherapy investigational agents",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "there must be at least a 3-week washout period after stopping any investigational cancer agent",
                        "criterion": "washout period after investigational cancer agent",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "week"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment with non-chemotherapy investigational agents is permitted",
                        "criterion": "prior treatment with non-chemotherapy investigational agents",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "there must be at least a 3-week washout period after stopping any investigational cancer agent",
                        "criterion": "washout period after investigational cancer agent",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "week"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                "criterions": [
                    {
                        "exact_snippets": "Male patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "sexually active",
                        "criterion": "sexual activity status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "number of forms",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "throughout the period of taking study treatment and for 3 months after last dose of study drug(s)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Male patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "sexually active",
                        "criterion": "sexual activity status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "number of forms",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "effectiveness",
                                    "expected_value": "highly effective"
                                }
                            },
                            {
                                "exact_snippets": "must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner",
                                "criterion": "contraception use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "throughout the period of taking study treatment and for 3 months after last dose of study drug(s)"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Documented histologically confirmed adenocarcinoma of the prostate",
                "criterions": [
                    {
                        "exact_snippets": "Documented histologically confirmed adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented histologically confirmed adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Documented histologically confirmed adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented histologically confirmed adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations",
                "criterions": [
                    {
                        "exact_snippets": "Patient is willing ... to comply with the protocol for the duration of the study",
                        "criterion": "willingness to comply with protocol",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patient is ... able to comply with the protocol for the duration of the study",
                        "criterion": "ability to comply with protocol",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including undergoing treatment",
                        "criterion": "ability to undergo treatment",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including ... scheduled visits and examinations",
                        "criterion": "ability to attend scheduled visits and examinations",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient is willing ... to comply with the protocol for the duration of the study",
                        "criterion": "willingness to comply with protocol",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patient is ... able to comply with the protocol for the duration of the study",
                        "criterion": "ability to comply with protocol",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including undergoing treatment",
                        "criterion": "ability to undergo treatment",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including ... scheduled visits and examinations",
                        "criterion": "ability to attend scheduled visits and examinations",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must have archival tissue available, be willing to undergo metastatic biopsy or have a sufficient plasma circulating tumor DNA (ctDNA) concentration in order to perform next-generation DNA sequencing",
                "criterions": [
                    {
                        "exact_snippets": "Must have archival tissue available",
                        "criterion": "archival tissue",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "be willing to undergo metastatic biopsy",
                        "criterion": "willingness to undergo metastatic biopsy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "have a sufficient plasma circulating tumor DNA (ctDNA) concentration in order to perform next-generation DNA sequencing",
                        "criterion": "plasma circulating tumor DNA (ctDNA) concentration",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "sufficient for next-generation DNA sequencing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Must have archival tissue available",
                        "criterion": "archival tissue",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "be willing to undergo metastatic biopsy",
                        "criterion": "willingness to undergo metastatic biopsy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "have a sufficient plasma circulating tumor DNA (ctDNA) concentration in order to perform next-generation DNA sequencing",
                        "criterion": "plasma circulating tumor DNA (ctDNA) concentration",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "sufficient for next-generation DNA sequencing"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to administration of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to administration of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior chemotherapy for the treatment of mCRPC; patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer",
                "criterions": [
                    {
                        "exact_snippets": "No prior chemotherapy for the treatment of mCRPC",
                        "criterion": "prior chemotherapy for mCRPC",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer",
                        "criterion": "prior docetaxel for hormone-sensitive prostate cancer",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior chemotherapy for the treatment of mCRPC",
                        "criterion": "prior chemotherapy for mCRPC",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "patients may have received docetaxel for the treatment of hormone-sensitive prostate cancer",
                        "criterion": "prior docetaxel for hormone-sensitive prostate cancer",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have progressed on abiraterone and/or enzalutamide; there must be at least a 3-week washout period after stopping the most recent approved therapy for mCRPC (i.e., abiraterone, enzalutamide, Ra-223, sipuleucel-t); if applicable, patients should be weaned off steroids at least 1 week prior to starting treatment",
                "criterions": [
                    {
                        "exact_snippets": "Patients must have progressed on abiraterone and/or enzalutamide",
                        "criterion": "progression on abiraterone and/or enzalutamide",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "there must be at least a 3-week washout period after stopping the most recent approved therapy for mCRPC (i.e., abiraterone, enzalutamide, Ra-223, sipuleucel-t)",
                        "criterion": "washout period after most recent approved mCRPC therapy",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients should be weaned off steroids at least 1 week prior to starting treatment",
                        "criterion": "weaning off steroids prior to treatment",
                        "requirement": {
                            "requirement_type": "weaned off steroids",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must have progressed on abiraterone and/or enzalutamide",
                        "criterion": "progression on abiraterone and/or enzalutamide",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "there must be at least a 3-week washout period after stopping the most recent approved therapy for mCRPC (i.e., abiraterone, enzalutamide, Ra-223, sipuleucel-t)",
                        "criterion": "washout period after most recent approved mCRPC therapy",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients should be weaned off steroids at least 1 week prior to starting treatment",
                        "criterion": "weaning off steroids prior to treatment",
                        "requirement": {
                            "requirement_type": "weaned off steroids",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PSA must be at least 1 ng/ml and rising on two successive measurements at least two weeks apart",
                "criterions": [
                    {
                        "exact_snippets": "PSA must be at least 1 ng/ml",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "ng/ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "trend",
                            "expected_value": "rising"
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "measurement_frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "measurements"
                            }
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "measurement_interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PSA must be at least 1 ng/ml",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "ng/ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "trend",
                            "expected_value": "rising"
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "measurement_frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "measurements"
                            }
                        }
                    },
                    {
                        "exact_snippets": "rising on two successive measurements at least two weeks apart",
                        "criterion": "PSA level",
                        "requirement": {
                            "requirement_type": "measurement_interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment",
                "criterions": [
                    {
                        "exact_snippets": "Patients receiving any systemic chemotherapy ... within 3 weeks prior to study treatment",
                        "criterion": "systemic chemotherapy",
                        "requirement": {
                            "requirement_type": "receipt within prior time period",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients receiving any ... radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "receipt within prior time period",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients receiving any ... radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment",
                        "criterion": "radiotherapy",
                        "requirement": {
                            "requirement_type": "purpose",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "palliative reasons"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Patients receiving any systemic chemotherapy ... within 3 weeks prior to study treatment",
                                "criterion": "systemic chemotherapy",
                                "requirement": {
                                    "requirement_type": "receipt within prior time period",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 3,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Patients receiving any ... radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment",
                                        "criterion": "radiotherapy",
                                        "requirement": {
                                            "requirement_type": "receipt within prior time period",
                                            "expected_value": {
                                                "operator": "=",
                                                "value": 3,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Patients receiving any ... radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment",
                                        "criterion": "radiotherapy",
                                        "requirement": {
                                            "requirement_type": "purpose",
                                            "expected_value": {
                                                "operator": "!=",
                                                "value": 1,
                                                "unit": "palliative reasons"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with a known hypersensitivity to olaparib or any of the excipients of the product",
                "criterions": [
                    {
                        "exact_snippets": "known hypersensitivity to olaparib",
                        "criterion": "hypersensitivity to olaparib",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known hypersensitivity to ... any of the excipients of the product",
                        "criterion": "hypersensitivity to excipients of the product",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known hypersensitivity to olaparib",
                        "criterion": "hypersensitivity to olaparib",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known hypersensitivity to ... any of the excipients of the product",
                        "criterion": "hypersensitivity to excipients of the product",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any previous treatment with poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, including olaparib",
                "criterions": [
                    {
                        "exact_snippets": "Any previous treatment with poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, including olaparib",
                        "criterion": "previous treatment with PARP inhibitor",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any previous treatment with poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, including olaparib",
                    "criterion": "previous treatment with PARP inhibitor",
                    "requirement": {
                        "requirement_type": "history of treatment",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                "criterions": [
                    {
                        "exact_snippets": "Any psychological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "psychological condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... familial ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "familial condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... sociological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "sociological condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "geographical condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any psychological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "psychological condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... familial ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "familial condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... sociological ... condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "sociological condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any ... geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule",
                        "criterion": "geographical condition",
                        "requirement": {
                            "requirement_type": "potential interference with compliance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy, excluding alopecia",
                "criterions": [
                    {
                        "exact_snippets": "Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy",
                        "criterion": "toxicities caused by previous cancer therapy",
                        "requirement": {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy",
                        "criterion": "toxicities caused by previous cancer therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "excluding alopecia",
                        "criterion": "alopecia",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy",
                                "criterion": "toxicities caused by previous cancer therapy",
                                "requirement": {
                                    "requirement_type": "persistence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Persistent toxicities (> Common Terminology Criteria for Adverse Event [CTCAE] grade 2) caused by previous cancer therapy",
                                "criterion": "toxicities caused by previous cancer therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 2,
                                        "unit": "CTCAE grade"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "excluding alopecia",
                            "criterion": "alopecia",
                            "requirement": {
                                "requirement_type": "exclusion",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Previous enrollment in this study",
                "criterions": [
                    {
                        "exact_snippets": "Previous enrollment in this study",
                        "criterion": "enrollment in this study",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previous enrollment in this study",
                    "criterion": "enrollment in this study",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participation in another clinical study with an investigational product during the last 3 weeks",
                "criterions": [
                    {
                        "exact_snippets": "Participation in another clinical study with an investigational product during the last 3 weeks",
                        "criterion": "participation in another clinical study with an investigational product",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participation in another clinical study with an investigational product during the last 3 weeks",
                        "criterion": "participation in another clinical study with an investigational product",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing medical ... condition ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing medical condition",
                        "requirement": {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    },
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing medical ... condition ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing medical condition",
                        "requirement": {
                            "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing ... psychiatric ... condition ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing psychiatric condition",
                        "requirement": {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    },
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing ... psychiatric ... condition ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing psychiatric condition",
                        "requirement": {
                            "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing ... other condition (including laboratory abnormalities) ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing other condition (including laboratory abnormalities)",
                        "requirement": {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        }
                    },
                    {
                        "exact_snippets": "Evidence of serious and/or unstable pre-existing ... other condition (including laboratory abnormalities) ... that could interfere with patient safety or provision of informed consent",
                        "criterion": "pre-existing other condition (including laboratory abnormalities)",
                        "requirement": {
                            "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing medical ... condition ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing medical condition",
                                "requirement": {
                                    "requirement_type": "seriousness or stability",
                                    "expected_value": "serious and/or unstable"
                                }
                            },
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing medical ... condition ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing medical condition",
                                "requirement": {
                                    "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing ... psychiatric ... condition ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing psychiatric condition",
                                "requirement": {
                                    "requirement_type": "seriousness or stability",
                                    "expected_value": "serious and/or unstable"
                                }
                            },
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing ... psychiatric ... condition ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing psychiatric condition",
                                "requirement": {
                                    "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing ... other condition (including laboratory abnormalities) ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing other condition (including laboratory abnormalities)",
                                "requirement": {
                                    "requirement_type": "seriousness or stability",
                                    "expected_value": "serious and/or unstable"
                                }
                            },
                            {
                                "exact_snippets": "Evidence of serious and/or unstable pre-existing ... other condition (including laboratory abnormalities) ... that could interfere with patient safety or provision of informed consent",
                                "criterion": "pre-existing other condition (including laboratory abnormalities)",
                                "requirement": {
                                    "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 2 weeks of starting study treatment",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients must have recovered from any effects of any major surgery",
                        "criterion": "recovery from major surgery",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Major surgery within 2 weeks of starting study treatment",
                            "criterion": "major surgery",
                            "requirement": {
                                "requirement_type": "time since surgery",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "patients must have recovered from any effects of any major surgery",
                            "criterion": "recovery from major surgery",
                            "requirement": {
                                "requirement_type": "recovery status",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication",
                "criterions": [
                    {
                        "exact_snippets": "Patients unable to swallow orally administered medication",
                        "criterion": "ability to swallow orally administered medication",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients with gastrointestinal disorders likely to interfere with absorption of the study medication",
                        "criterion": "gastrointestinal disorders interfering with absorption of study medication",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Patients unable to swallow orally administered medication",
                            "criterion": "ability to swallow orally administered medication",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "patients with gastrointestinal disorders likely to interfere with absorption of the study medication",
                            "criterion": "gastrointestinal disorders interfering with absorption of study medication",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)",
                "criterions": [
                    {
                        "exact_snippets": "Previous allogenic bone marrow transplant",
                        "criterion": "allogenic bone marrow transplant",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "double umbilical cord blood transplantation (dUCBT)",
                        "criterion": "double umbilical cord blood transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Previous allogenic bone marrow transplant",
                        "criterion": "allogenic bone marrow transplant",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "double umbilical cord blood transplantation (dUCBT)",
                        "criterion": "double umbilical cord blood transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with pain attributable to their prostate cancer",
                "criterions": [
                    {
                        "exact_snippets": "pain attributable to their prostate cancer",
                        "criterion": "pain attributable to prostate cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "pain attributable to their prostate cancer",
                    "criterion": "pain attributable to prostate cancer",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome",
                "criterions": [
                    {
                        "exact_snippets": "Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.)",
                        "criterion": "cardiac conditions",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.)",
                        "criterion": "cardiac conditions",
                        "requirement": {
                            "requirement_type": "reversibility",
                            "expected_value": "potentially reversible"
                        }
                    },
                    {
                        "exact_snippets": "unstable ischemia",
                        "criterion": "ischemia",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled symptomatic arrhythmia",
                        "criterion": "symptomatic arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Fridericia's corrected QT interval [QTcF] prolongation > 500 ms",
                        "criterion": "Fridericia's corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "electrolyte disturbances",
                        "criterion": "electrolyte disturbances",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients with congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.)",
                                "criterion": "cardiac conditions",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's corrected QT interval [QTcF] prolongation > 500 ms, electrolyte disturbances, etc.)",
                                "criterion": "cardiac conditions",
                                "requirement": {
                                    "requirement_type": "reversibility",
                                    "expected_value": "potentially reversible"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "unstable ischemia",
                        "criterion": "ischemia",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled symptomatic arrhythmia",
                        "criterion": "symptomatic arrhythmia",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Fridericia's corrected QT interval [QTcF] prolongation > 500 ms",
                        "criterion": "Fridericia's corrected QT interval (QTcF)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "electrolyte disturbances",
                        "criterion": "electrolyte disturbances",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients with congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction)",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy",
                        "criterion": "disease risk from testosterone therapy",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "femoral metastases with concern over fracture risk",
                        "criterion": "femoral metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "femoral metastases with concern over fracture risk",
                        "criterion": "femoral metastases",
                        "requirement": {
                            "requirement_type": "fracture risk",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "spinal metastases with concern over spinal cord compression",
                        "criterion": "spinal metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "spinal metastases with concern over spinal cord compression",
                        "criterion": "spinal metastases",
                        "requirement": {
                            "requirement_type": "spinal cord compression risk",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lymph node disease with concern for ureteral obstruction",
                        "criterion": "lymph node disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lymph node disease with concern for ureteral obstruction",
                        "criterion": "lymph node disease",
                        "requirement": {
                            "requirement_type": "ureteral obstruction risk",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy",
                        "criterion": "disease risk from testosterone therapy",
                        "requirement": {
                            "requirement_type": "risk assessment",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "femoral metastases with concern over fracture risk",
                                "criterion": "femoral metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "femoral metastases with concern over fracture risk",
                                "criterion": "femoral metastases",
                                "requirement": {
                                    "requirement_type": "fracture risk",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "spinal metastases with concern over spinal cord compression",
                                "criterion": "spinal metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "spinal metastases with concern over spinal cord compression",
                                "criterion": "spinal metastases",
                                "requirement": {
                                    "requirement_type": "spinal cord compression risk",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "lymph node disease with concern for ureteral obstruction",
                                "criterion": "lymph node disease",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "lymph node disease with concern for ureteral obstruction",
                                "criterion": "lymph node disease",
                                "requirement": {
                                    "requirement_type": "ureteral obstruction risk",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)",
                "criterions": [
                    {
                        "exact_snippets": "Immunocompromised patients",
                        "criterion": "immunocompromised status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients who are known to be serologically positive for human immunodeficiency virus (HIV)",
                        "criterion": "HIV seropositivity",
                        "requirement": {
                            "requirement_type": "serological positivity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Immunocompromised patients",
                        "criterion": "immunocompromised status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients who are known to be serologically positive for human immunodeficiency virus (HIV)",
                        "criterion": "HIV seropositivity",
                        "requirement": {
                            "requirement_type": "serological positivity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, history of prior myocardial infarction, uncontrolled major seizure disorder, uncontrolled hypertension (blood pressure [BP] ≥ 160/100), history of prior stroke, uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7), unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent",
                "criterions": [
                    {
                        "exact_snippets": "serious, uncontrolled medical disorder",
                        "criterion": "medical disorder",
                        "requirement": {
                            "requirement_type": "seriousness",
                            "expected_value": "serious"
                        }
                    },
                    {
                        "exact_snippets": "serious, uncontrolled medical disorder",
                        "criterion": "medical disorder",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "non-malignant systemic disease",
                        "criterion": "systemic disease",
                        "requirement": {
                            "requirement_type": "malignancy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "active, uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active, uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled ventricular arrhythmia",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of prior myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled major seizure disorder",
                        "criterion": "major seizure disorder",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mmHg systolic"
                            }
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mmHg diastolic"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of prior stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7)",
                        "criterion": "diabetes",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7)",
                        "criterion": "diabetes",
                        "requirement": {
                            "requirement_type": "glycosylated hemoglobin [hgb A1C]",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable spinal cord compression",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "superior vena cava syndrome",
                        "criterion": "superior vena cava syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan",
                        "criterion": "interstitial bilateral lung disease",
                        "requirement": {
                            "requirement_type": "extent",
                            "expected_value": "extensive"
                        }
                    },
                    {
                        "exact_snippets": "extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan",
                        "criterion": "interstitial bilateral lung disease",
                        "requirement": {
                            "requirement_type": "diagnosis method",
                            "expected_value": "high resolution computed tomography (HRCT) scan"
                        }
                    },
                    {
                        "exact_snippets": "any psychiatric disorder that prohibits obtaining informed consent",
                        "criterion": "psychiatric disorder",
                        "requirement": {
                            "requirement_type": "effect on consent",
                            "expected_value": "prohibits obtaining informed consent"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "serious, uncontrolled medical disorder",
                                "criterion": "medical disorder",
                                "requirement": {
                                    "requirement_type": "seriousness",
                                    "expected_value": "serious"
                                }
                            },
                            {
                                "exact_snippets": "serious, uncontrolled medical disorder",
                                "criterion": "medical disorder",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "non-malignant systemic disease",
                        "criterion": "systemic disease",
                        "requirement": {
                            "requirement_type": "malignancy",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active, uncontrolled infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active, uncontrolled infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "uncontrolled ventricular arrhythmia",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of prior myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled major seizure disorder",
                        "criterion": "major seizure disorder",
                        "requirement": {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "blood pressure",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 160,
                                        "unit": "mmHg systolic"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "uncontrolled hypertension (blood pressure [BP] ≥ 160/100)",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "blood pressure",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "mmHg diastolic"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "history of prior stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7)",
                                "criterion": "diabetes",
                                "requirement": {
                                    "requirement_type": "control",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "uncontrolled diabetes (glycosylated hemoglobin [hgb A1C] > 7)",
                                "criterion": "diabetes",
                                "requirement": {
                                    "requirement_type": "glycosylated hemoglobin [hgb A1C]",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 7,
                                        "unit": ""
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "unstable spinal cord compression",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "superior vena cava syndrome",
                        "criterion": "superior vena cava syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan",
                                "criterion": "interstitial bilateral lung disease",
                                "requirement": {
                                    "requirement_type": "extent",
                                    "expected_value": "extensive"
                                }
                            },
                            {
                                "exact_snippets": "extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan",
                                "criterion": "interstitial bilateral lung disease",
                                "requirement": {
                                    "requirement_type": "diagnosis method",
                                    "expected_value": "high resolution computed tomography (HRCT) scan"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "any psychiatric disorder that prohibits obtaining informed consent",
                        "criterion": "psychiatric disorder",
                        "requirement": {
                            "requirement_type": "effect on consent",
                            "expected_value": "prohibits obtaining informed consent"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)",
                "criterions": [
                    {
                        "exact_snippets": "Patients with myelodysplastic syndrome/acute myeloid leukemia",
                        "criterion": "myelodysplastic syndrome or acute myeloid leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)",
                        "criterion": "features suggestive of myelodysplastic syndrome or acute myeloid leukemia",
                        "requirement": {
                            "requirement_type": "suggestive features",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients with myelodysplastic syndrome/acute myeloid leukemia",
                        "criterion": "myelodysplastic syndrome or acute myeloid leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)",
                        "criterion": "features suggestive of myelodysplastic syndrome or acute myeloid leukemia",
                        "requirement": {
                            "requirement_type": "suggestive features",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of deep venous thrombosis ... within 5 years prior to enrollment",
                        "criterion": "deep venous thrombosis",
                        "requirement": {
                            "requirement_type": "history_within_years",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior history of ... pulmonary embolism within 5 years prior to enrollment",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "history_within_years",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "not currently on systemic anticoagulation",
                        "criterion": "systemic anticoagulation",
                        "requirement": {
                            "requirement_type": "current_use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Prior history of deep venous thrombosis ... within 5 years prior to enrollment",
                                "criterion": "deep venous thrombosis",
                                "requirement": {
                                    "requirement_type": "history_within_years",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Prior history of ... pulmonary embolism within 5 years prior to enrollment",
                                "criterion": "pulmonary embolism",
                                "requirement": {
                                    "requirement_type": "history_within_years",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "not currently on systemic anticoagulation",
                        "criterion": "systemic anticoagulation",
                        "requirement": {
                            "requirement_type": "current_use",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with a known hypersensitivity to the testosterone cypionate or any of the excipients of the product",
                "criterions": [
                    {
                        "exact_snippets": "known hypersensitivity to the testosterone cypionate",
                        "criterion": "hypersensitivity to testosterone cypionate",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known hypersensitivity to ... any of the excipients of the product",
                        "criterion": "hypersensitivity to excipients of the product",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known hypersensitivity to the testosterone cypionate",
                        "criterion": "hypersensitivity to testosterone cypionate",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known hypersensitivity to ... any of the excipients of the product",
                        "criterion": "hypersensitivity to excipients of the product",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1.5 x 10^9/L",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e., ≤ 50 mg/dL)",
                "criterions": [
                    {
                        "exact_snippets": "evidence of castration resistant prostate cancer",
                        "criterion": "castration resistant prostate cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria)",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "per PCWG3 criteria",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "castrate serum testosterone level (i.e., ≤ 50 mg/dL)",
                        "criterion": "serum testosterone level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "evidence of castration resistant prostate cancer",
                        "criterion": "castration resistant prostate cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "PSA progression (per Prostate Cancer Working Group 3 [PCWG3] criteria)",
                        "criterion": "PSA progression",
                        "requirement": {
                            "requirement_type": "per PCWG3 criteria",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "castrate serum testosterone level (i.e., \u00103 50 mg/dL)",
                        "criterion": "serum testosterone level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan and is suitable for repeated assessment",
                "criterions": [
                    {
                        "exact_snippets": "At least one lesion (measurable and/or non-measurable)",
                        "criterion": "lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "can be accurately assessed at baseline by computed tomography (CT), positron-emission tomography (PET), magnetic resonance imaging (MRI) and/or bone scan",
                        "criterion": "lesion imaging assessment",
                        "requirement": {
                            "requirement_type": "assessability by imaging",
                            "expected_value": [
                                "CT",
                                "PET",
                                "MRI",
                                "bone scan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "suitable for repeated assessment",
                        "criterion": "lesion suitability for repeated assessment",
                        "requirement": {
                            "requirement_type": "suitability for repeated assessment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 10.0 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no blood transfusion in the past 28 days (within 28 days prior to administration of study treatment)",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 28 days prior to study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u001e 10.0 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no blood transfusion in the past 28 days (within 28 days prior to administration of study treatment)",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 28 days prior to study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥ 100 x 10^9/L (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 100 x 10^9/L (within 28 days prior to administration of study treatment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count ≥ 100 x 10^9/L (within 28 days prior to administration of study treatment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to administration of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 100 x 10^9/L (within 28 days prior to administration of study treatment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count \u001e 100 x 10^9/L (within 28 days prior to administration of study treatment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to administration of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have creatinine clearance estimated using the Cockcroft-Gault equation or based on a 24 hour urine test of ≥ 51 mL/min (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "creatinine clearance estimated using the Cockcroft-Gault equation or based on a 24 hour urine test of ≥ 51 mL/min (within 28 days prior to administration of study treatment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "estimation method",
                            "expected_value": [
                                "Cockcroft-Gault equation",
                                "24 hour urine test"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance estimated using the Cockcroft-Gault equation or based on a 24 hour urine test of ≥ 51 mL/min (within 28 days prior to administration of study treatment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 51,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine clearance estimated using the Cockcroft-Gault equation or based on a 24 hour urine test of ≥ 51 mL/min (within 28 days prior to administration of study treatment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to administration of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have a life expectancy ≥ 16 weeks",
                "criterions": [
                    {
                        "exact_snippets": "life expectancy ≥ 16 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "life expectancy \u00100 16 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5 x ULN (within 28 days prior to administration of study treatment)",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5 x ULN",
                        "criterion": "AST/ALT levels",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless liver metastases are present in which case they must be ≤ 5 x ULN",
                        "criterion": "AST/ALT levels (with liver metastases)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "unless liver metastases are present",
                    "criterion": "liver metastases",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "unless liver metastases are present in which case they must be ≤ 5 x ULN",
                    "criterion": "AST/ALT levels (with liver metastases)",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "x ULN"
                                }
                            ]
                        }
                    }
                },
                "else_criteria": {
                    "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5 x ULN",
                    "criterion": "AST/ALT levels",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 2.5,
                                    "unit": "x ULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* The study will require that 50% of enrolled subjects have homozygous deletions, deleterious mutations, or both in one or more of the DNA damage response (DDR) genes; the other 50% of patients must have an intact DDR pathway",
                "criterions": [
                    {
                        "exact_snippets": "50% of enrolled subjects have homozygous deletions, deleterious mutations, or both in one or more of the DNA damage response (DDR) genes",
                        "criterion": "DNA damage response (DDR) gene status",
                        "requirement": {
                            "requirement_type": "genetic alteration",
                            "expected_value": [
                                "homozygous deletion",
                                "deleterious mutation"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "the other 50% of patients must have an intact DDR pathway",
                        "criterion": "DNA damage response (DDR) pathway status",
                        "requirement": {
                            "requirement_type": "pathway integrity",
                            "expected_value": "intact"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil); the required washout period prior to starting olaparib is 2 weeks",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir)",
                        "criterion": "concomitant use of strong CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Concomitant use of ... moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil)",
                        "criterion": "concomitant use of moderate CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "the required washout period prior to starting olaparib is 2 weeks",
                        "criterion": "washout period for CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir)",
                                "criterion": "concomitant use of strong CYP3A inhibitors",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "the required washout period prior to starting olaparib is 2 weeks",
                                "criterion": "washout period for CYP3A inhibitors",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Concomitant use of ... moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil)",
                                "criterion": "concomitant use of moderate CYP3A inhibitors",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "the required washout period prior to starting olaparib is 2 weeks",
                                "criterion": "washout period for CYP3A inhibitors",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)",
                "criterions": [
                    {
                        "exact_snippets": "Whole blood transfusions in the last 120 days prior to entry to the study",
                        "criterion": "whole blood transfusions",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Whole blood transfusions in the last 120 days prior to entry to the study",
                        "criterion": "whole blood transfusions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Whole blood transfusions in the last 120 days prior to entry to the study",
                                "criterion": "whole blood transfusions",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 120,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Whole blood transfusions in the last 120 days prior to entry to the study",
                                "criterion": "whole blood transfusions",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil); the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil)",
                        "criterion": "concomitant use of strong or moderate CYP3A inducers",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                        "criterion": "washout period for CYP3A inducers",
                        "requirement": {
                            "requirement_type": "duration for enzalutamide",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                        "criterion": "washout period for CYP3A inducers",
                        "requirement": {
                            "requirement_type": "duration for phenobarbital",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                        "criterion": "washout period for CYP3A inducers",
                        "requirement": {
                            "requirement_type": "duration for other agents",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil)",
                        "criterion": "concomitant use of strong or moderate CYP3A inducers",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                                "criterion": "washout period for CYP3A inducers",
                                "requirement": {
                                    "requirement_type": "duration for enzalutamide",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                                "criterion": "washout period for CYP3A inducers",
                                "requirement": {
                                    "requirement_type": "duration for phenobarbital",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "the required washout period prior to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks for other agents",
                                "criterion": "washout period for CYP3A inducers",
                                "requirement": {
                                    "requirement_type": "duration for other agents",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with symptomatic uncontrolled brain metastases; a scan to confirm the absence of brain metastases is not required; the patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment; patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days",
                "criterions": [
                    {
                        "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "the patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment",
                        "criterion": "corticosteroid use",
                        "requirement": {
                            "requirement_type": "dose_stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "the patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment",
                        "criterion": "corticosteroid use",
                        "requirement": {
                            "requirement_type": "start_time_before_treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "definitive_treatment_received",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "clinically_stable_disease_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "symptomatic",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with symptomatic uncontrolled brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days",
                                "criterion": "spinal cord compression",
                                "requirement": {
                                    "requirement_type": "definitive_treatment_received",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days",
                                "criterion": "spinal cord compression",
                                "requirement": {
                                    "requirement_type": "clinically_stable_disease_duration",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)",
                "criterions": [
                    {
                        "exact_snippets": "Involvement in the planning and/or conduct of the study",
                        "criterion": "involvement in the planning and/or conduct of the study",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "AstraZeneca staff and/or staff at the study site",
                        "criterion": "employment affiliation",
                        "requirement": {
                            "requirement_type": "affiliation",
                            "expected_value": [
                                "AstraZeneca staff",
                                "staff at the study site"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids",
                "criterions": [
                    {
                        "exact_snippets": "Patients with known active hepatitis (i.e., hepatitis B or C)",
                        "criterion": "active hepatitis infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with known active hepatitis (i.e., hepatitis B or C)",
                        "criterion": "active hepatitis infection",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "hepatitis B",
                                "hepatitis C"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Tumor causing urinary outlet obstruction that requires catheterization for voiding; patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll",
                "criterions": [
                    {
                        "exact_snippets": "Tumor causing urinary outlet obstruction that requires catheterization for voiding",
                        "criterion": "urinary outlet obstruction due to tumor",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Tumor causing urinary outlet obstruction that requires catheterization for voiding",
                        "criterion": "urinary outlet obstruction due to tumor",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": "tumor"
                        }
                    },
                    {
                        "exact_snippets": "Tumor causing urinary outlet obstruction that requires catheterization for voiding",
                        "criterion": "urinary outlet obstruction due to tumor",
                        "requirement": {
                            "requirement_type": "requires catheterization for voiding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll",
                        "criterion": "catheterization for voiding due to benign strictures or other non-cancer causes",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "benign strictures",
                                "other non-cancer causes"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll",
                        "criterion": "catheterization for voiding due to benign strictures or other non-cancer causes",
                        "requirement": {
                            "requirement_type": "requires catheterization for voiding",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll",
                        "criterion": "catheterization for voiding due to benign strictures or other non-cancer causes",
                        "requirement": {
                            "requirement_type": "enrollment permission",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years except: adequately treated non-melanoma skin cancer",
                "criterions": [
                    {
                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years",
                        "criterion": "other malignancy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years",
                        "criterion": "other malignancy",
                        "requirement": {
                            "requirement_type": "curative treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years",
                        "criterion": "other malignancy",
                        "requirement": {
                            "requirement_type": "evidence of disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "except: adequately treated non-melanoma skin cancer",
                        "criterion": "non-melanoma skin cancer",
                        "requirement": {
                            "requirement_type": "treatment adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for \u001e 5 years",
                                        "criterion": "other malignancy",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for \u001e 5 years",
                                        "criterion": "other malignancy",
                                        "requirement": {
                                            "requirement_type": "curative treatment",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for \u001e 5 years",
                                        "criterion": "other malignancy",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for \u001e 5 years",
                                        "criterion": "other malignancy",
                                        "requirement": {
                                            "requirement_type": "curative treatment",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Other malignancy unless curatively treated with no evidence of disease for \u001e 5 years",
                                        "criterion": "other malignancy",
                                        "requirement": {
                                            "requirement_type": "evidence of disease-free interval",
                                            "expected_value": {
                                                "operator": "<",
                                                "value": 5,
                                                "unit": "years"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "except: adequately treated non-melanoma skin cancer",
                                "criterion": "non-melanoma skin cancer",
                                "requirement": {
                                    "requirement_type": "treatment adequacy",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) prior to enrollment in the study",
                "criterions": [
                    {
                        "exact_snippets": "NYHA (New York Heart Association) class III or IV heart failure",
                        "criterion": "NYHA heart failure class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "history of a prior myocardial infarction (MI) prior to enrollment in the study",
                        "criterion": "history of myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}